Remove issue health-care-reform
article thumbnail

STAT+: Health care lobbying giants spent big as little got done in Congress

STAT

The Pharmaceutical Care Management Association, the industry’s biggest trade group, spent a whopping 71% more on lobbying in the first three months of this year compared with 2023, increasing its spending from $2.8 The odds were stacked against the middlemen between drugmakers and health insurers during this round of negotiations.

Packaging 327
article thumbnail

STAT+: Key Senate panel eyes action on drug shortages

STAT

WASHINGTON — One of the top health care committees in the Senate is assembling ideas for bipartisan legislation to address drug shortages, three Senate aides and three lobbyists told STAT. and ranking member Mike Crapo (R-Idaho) are in the early days, but they could move the debate over drug shortage reforms into a new phase.

Hospitals 262
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

STAT+: States increasingly look to regulate hospital facility fees

STAT

A new report, published by Georgetown University’s Center on Health Insurance Reforms and West Health, examined 11 states that regulate facility fees and conducted interviews with numerous government officials, patient advocates, health insurers, hospitals, and billing experts.

Hospitals 220
article thumbnail

ASBM Chair Advocates for PBM Reform on Capitol Hill

Safe Biologics

The advocacy conference brought together patient advocates, health care providers, and industry representatives from the major national voluntary and professional societies concerned with digestive diseases. This year’s theme was “Improving Patient Care.”

Diabetes 100
article thumbnail

STAT+: Pharmalittle: Novo faces patent challenge on Wegovy and Ozempic; Senate panel moves to address drug shortages

STAT

… One of the top health care committees in the Senate is assembling ideas for bipartisan legislation to address drug shortages , according to STAT. and ranking member Mike Crapo (R-Idaho), are in the early days, but they could move the debate over drug-shortage reforms into a new phase. The talks, led by U.S.

Dosage 250
article thumbnail

Guest Post: Now is the Time to Act for Patients

Putting Patients First Blog

GUEST POST: Now is the Time to Act for Patients April 3, 2024 By: Robert Anderson, VP of Corporate Affairs, Boehringer Ingelheim USA Corporation; President, Boehringer Cares Foundation At Boehringer Ingelheim, we believe in taking action. We need larger system reforms to bring forward long-term solutions. Terms and conditions apply.

article thumbnail

Guest Post: Now is the Time to Act for Patients

Putting Patients First Blog

GUEST POST: Now is the Time to Act for Patients April 3, 2024 By: Robert Anderson, VP of Corporate Affairs, Boehringer Ingelheim USA Corporation; President, Boehringer Cares Foundation At Boehringer Ingelheim, we believe in taking action. We need larger system reforms to bring forward long-term solutions. Terms and conditions apply.